Page 70 - Read Online

Enrique et al. J Cancer Metastasis Treat 2019;5:54 I http://dx.doi.org/10.20517/2394-4722.2019.20 Page 15 of 16

metastases. Tumour Biol 2017;39:1010428317710030.
28. Usinskiene J, Ulyte A, Bjørnerud A, Venius J, Katsaros VK, et al. Optimal differentiation of high- and low-grade glioma and metastasis:
a meta-analysis of perfusion, diffusion, and spectroscopy metrics. Neuroradiology 2016;58:339-50.
29. Fan G, Sun B, Wu Z, Guo Q, Guo Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and
solitary metastases. Clin Radiol 2004;59:77-85.
30. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors
in adults. Radiographics 2006;26 Suppl 1: S173-89.
31. Horská A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am 2010;20:293-310.
32. Verma A, Kumar I, Verma N, Aggarwal P, Ojha R. Magnetic resonance spectroscopy: Revisiting the biochemical and molecular milieu
of brain tumors. BBA Clin 2016;5:170-8.
33. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet
1961;81:46-53.
34. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, et al. The role of steroids in the management of brain metastases:
a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:103-14.
35. Forster C, Silwedel C, Golenhofen N, Burek M, Kietz S, et al. Occludin as direct target for glucocorticoid-induced improvement of
blood–brain barrier properties in a murine in vitro system. J Physiol 2005;565:475-86.
36. Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, et al. Anticonvulsant prophylaxis and steroid use in adults with
metastatic brain tumors: ASCO and SNO endorsement of the congress of neurological surgeons guidelines. J Clin Oncol 2019;37:1130-5.
37. Perry J, Zinman L, Chambers A, Spithoff K, Lloyd N, et al. The use of prophylactic anticonvulsants in patients with brain tumours: a
systematic review. Curr Oncol 2006;13:222-9.
38. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, et al. Occludin: a novel integral membrane protein localizing at tight junctions.
J Cell Biol 1993;123:1777-88.
39. Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, et al. Antiepileptics in brain metastases: safety, efficacy and impact on life
expectancy. J Neurooncol 2010;98:109-16.
40. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation
therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
41. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain
metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-6.
42. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, et al. Summary report on the graded prognostic assessment: an accurate and facile
diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25.
43. Villà S, Weber DC, Moretones C, Mañes A, Combescure C, et al. Validation of the new graded prognostic assessment scale for brain
metastases: a multicenter prospective study. Radiat Oncol 2011;6:23.
44. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, et al. Radiotherapeutic and surgical management for newly diagnosed brain
metastases: an American society for radiation oncology evidence based guideline. Prac Radiat Oncol 2012;2:210-25.
45. Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. Cancer 1954;7:682-9.
46. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, et al. Use of normal tissue complication probability models in the clinic.
Int J Radiat Oncol Biol Phys 2010;76:S10-9.
47. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, et al. The palliation of brain metastases: Final results of the first two studies by
the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1980;6:1-9.
48. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain
metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-6.
49. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, et al. Summary report on the graded prognostic assessment: an accurate and facile
diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25.
50. Rades D, Bohlen G, Dunst J, Lohynska R, Veninga T, et al. Comparison of short-course versus long-course whole-brain radiotherapy in
the treatment of brain metastases. Strahlenther Onkol 2008;184:30-5.
51. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, et al. Whole brain radiation therapy with or without stereotactic
radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet
2004;363:1665-72.
52. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic
radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
53. O’Beirn M, Benghiat H, Meade S, Heyes G, Sawlani V, et al. The expanding role of radiosurgery for brain metastases. Medicines (Basel)
2018;5:E90.
54. David Roberge, Parney I, Brown PD. Radiosurgery to the postoperative surgical cavity: who needs evidence? Int J Radiation Oncol Biol
Phys 2012;83:486-93.
55. Flores BC, Patel AR, Timmerman RD, Barnett SL. From patchell to brown: an evidence-based evolution of the role of radiotherapy on
the management of brain metastases. World Neurosurg 2016;85:10-4.
56. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, et al. A randomized trial of surgery in the treatment of single metastases
to the brain. N Engl J Med 1990;322:494-500.
57. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, et al. Postoperative radiotherapy in the treatment of single metastases
to the brain: a randomized trial. JAMA 1998;280:1485-9.